# The TIME-2b Study: A Study of AKB-9778 (Razuprotafib), a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR)

> **NCT03197870** · PHASE2 · COMPLETED · sponsor: **EyePoint Pharmaceuticals, Inc.** · enrollment: 167 (actual)

## Conditions studied

- Nonproliferative Diabetic Retinopathy

## Interventions

- **DRUG:** AKB-9778
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03197870
- **Lead sponsor:** EyePoint Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-09
- **Primary completion:** 2019-01-09
- **Final completion:** 2019-02-09
- **Target enrollment:** 167 (ACTUAL)
- **Last updated:** 2023-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03197870

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03197870, "The TIME-2b Study: A Study of AKB-9778 (Razuprotafib), a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR)". Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/clinical/NCT03197870. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*